Angels for Change (A4C) successfully concluded its sold out SummitONE 2026, its annual healthcare summit focused on strengthening pharmaceutical supply chain resilience, at Pfizer's headquarters in New York City. The two-day event brought together executives and experts from across the pharmaceutical ecosystem; including manufacturers, distributors, healthcare systems, regulators, policymakers, and patient advocates. SummitONE advances collaboration and actionable solutions to strengthen access to medicines and end drug shortages.

Project GOLD is growing. Building on the success of its groundbreaking first phase, Angels for Change has launched Project GOLD Phase 2, expanding the nation's first collaborative initiative designed to protect cancer patients from drug shortages. With new manufacturer and distributor partners and an expanded portfolio of 15 high-risk oncology medicines, Phase 2 strengthens a proven model built on strategic U.S.-based buffer supply, early warning systems, and cross-sector collaboration. Following the successful protection of patient access during the national leucovorin shortage, Project GOLD continues to demonstrate that when industry leaders unite around a shared commitment to patients, together we can build a more resilient pharmaceutical supply chain and help ensure lifesaving cancer treatments remain available when patients need them most.

The newest Change Maker Chronicle is here! Drug shortages are still impacting patients every day, but together we are pushing forward. See how we’re raising awareness, fostering advocacy, and building resilent drug supply chains to end drug shortages NOW.

Angels for Change, through its Change Makers Institute, today announced the release of a new white paper, How Buffer Stock, Proactive Coordination, and Patient Advocacy Have Become a National Lifeline for Cancer Patients, highlighting the development and success of Project GOLD (Generic Oncology Lifesaving Drugs).

Drug shortages continue to put patients at risk, threatening access to lifesaving cancer treatments and creating uncertainty for healthcare providers who are often forced to make urgent, real-time decisions about patient care.